Hematologic malignancies: Where do we stand in 2011?

Journal of Clinical Oncology

Volumn 29, Issue 5, 2011, Pages 473-474

  Kantarjian, Hagop ^a   Schiffer, Charles ^b   Burnett, Alan ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CHLORODEOXYADENOSINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; FLUDARABINE; IMATINIB; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; NILOTINIB; PENTOSTATIN; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE MUTATION; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FUSION PROTEINS, BCR-ABL; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; PROTEIN KINASE INHIBITORS;

EID: 79952087451     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.8897     Document Type: Short Survey

References (0)